Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Drugs Made In America Acquisition (DMAA) Shares Outstanding (Weighted Average) (2024 - 2025)

Drugs Made In America Acquisition filings provide 2 years of Shares Outstanding (Weighted Average) readings, the most recent being $21.0 million for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 145.1% to $21.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.0 million through Dec 2025, up 145.1% year-over-year, with the annual reading at $21.0 million for FY2025, 145.1% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $21.0 million in Q4 2025 for Drugs Made In America Acquisition, up from $20.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $21.0 million in Q4 2025 and bottomed at $8.6 million in Q4 2024.